Table 1 Incidence of oral candidiasis during interleukin (IL)-17 inhibitors treatment of psoriatic patients and psoriatic arthritis
References | Disease | Number of patient | Treatment regimen | % (n) Oral candidiasis |
|---|---|---|---|---|
Langley et al. [5] | Psoriasis | 349 | Secukinumab 300 mg | 2% (7) |
353 | Secukinumab 150 mg weeks 12–52 | 0.8% (3) | ||
Blauvelt et al. [15] | Psoriasis | 59 | Secukinumab 300 mg 12 weeks | 1.7% (1) |
Thaçi et al. [17] | Psoriasis | 21 | Secukinumab 300 mg 36 weeks | 4.8% (1) |
Mease et al. [18] | Psoriatic Arthritis | 295 | Secukinumab 150 mg | 1.4% (4) |
292 | Secukinumab 75 mg 52 weeks | 1.4% (4) | ||
McInnes et al. [19] | Psoriatic Arthritis | 100 | Secukinumab 300 mg | 2% (2) |
100 | Secukinumab 150 mg | 2% (2) | ||
99 | Secukinumab 75 mg 52 weeks | 1% (1) | ||
Papp et al. [20] | Psoriasis | 181 | Brodalumab 210 mg Every 2 week | 2.8% (5) |
Nakagawa et al. [21] | Psoriasis | 37 | Brodalumab 210 mg 12 weeks | 2.7% (1) |
Yamasaki et al. [22] | Psoriasis | 30 | Brodalumab 140 mg 12 weeks | 3.3% (1) |
Gordon et al. [23] | Psoriasis | 3736 | Ixekizumab 80 mg 60 weeks | 1.7% (63) |